If the affected child is a genetic female, she, too, will be a carrier. An affected 46,XY child will have AIS.A genetic female with mutations in both AR genes could theoretically result from the union of a fertile man with AIS and a female carrier of the gene, or from de novo mutation. However, given the scarcity of fertile AIS men and low incidence of AR mutation, the chances of this occurrence are small. The phenotype of such an individual is a matter of speculation; as of 2010, no such documented case has been published. Correlation of genotype and phenotype
Individuals with partial AIS, unlike those with the complete or mild forms, present at birth with ambiguous genitalia, and the decision to raise the child as male or female is often not obvious. Unfortunately,  little information regarding phenotype can be gleaned from precise knowledge of the AR mutation itself;  the same AR mutation may cause significant variation in the degree of masculinization in different individuals, even among members of the same family.
A patent to use digoxin immunoglobulins C07k16/44 as a regulator of the preeclamptic/eclamptic patients sodium/potassium ATPase activity was approved in 2003 to Charles David Adair under application number WO2004011028A1. Commercial aspects
Price increase was reported to range from US $380 to US $750 during 2013 for digoxin-Fab. However, these price increases are not reflective of the United States average AWP for digoxin-Fab as it represents Australian costs converted to US. Prior to 2011, Digibind and DigiFab pricing was US $797 per 38 mg vial and US $786 per 40 mg vial respectively. After GSK discontinued Digibind sale in USA in 2011, the AWP of DigiFab increases by 15% to US $903 per 40 mg vial. AWP of DigiFab has continued to increase as much as 54% occurring in March 2014 to US $2,370 per 40 mg vial. However, the cost may vary depending on wholesaler contractor manufacturer rebates. References
External links
Drug information online
Digibind description